SciSparc Announces Positive Topline Results For Proprietary Pain Management Compound In Pre-Clinical Study


Study Results Indicate SCI-160 Has A Significant Analgesic Effect on Acute and Chronic Pain   TEL AVIV, Israel, Aug. 2, 2021 /PRNewswire/ — SciSparc Ltd. (OTCQB: SPRCY) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced positive top-line results for its proprietary compound, SCI-160 in a controlled pre-clinical trial on neuropathic and post-operative pain.   The study, “An evaluation of SCI-160 on neuropathic pain in the rat spared nerve injury (SNI) model and post-surgical pain in the rat hind paw incision model,” was designed to help assess the potential of SCI-160, the Company’s proprietary compound.   Key findings from the pre-clinical trial are as follows: SCI-160 significantly alleviates pain up to 6 hours after injection as compared with vehicle-treated animals Daily SCI-160 injections significantly alleviate subject pain from mechanical stimuli as compared with vehicle-treated animals, for up to 7 days after surgery Daily injections of SCI-160 significantly alleviate pain in a hind paw incision model of post-surgical pain up to 4 days post surgery as compared with vehicle treated animals SCI-160 analgesic effects are prolonged in the presence of palmitoylethanolamide (PEA)   Collectively, the results indicate that treatment with SCI-160 significantly alleviates both chronic and acute pain.   Dr. Adi Zuloff-Shani, PhD, Chief Technologies Officer of SciSparc, commented, “We are thrilled by this report; the findings corroborate results of previous SCI-160 pre-clinical studies. This growing body of evidence supports our vision of SCI-160 as a potential non-opioid option for the treatment of both chronic and post-surgical pain and validates our continuing development of this proprietary drug candidate for the clinical phase under FDA regulation.”   A study conducted by The G4 Alliance reports 300 million surgical procedures are performed annually, with an estimated 60 to 70% of patients experiencing moderate to severe pain just after 24 hours of surgery. The global…

Excerpt only …
Source : SciSparc Announces Positive Topline Results For Proprietary Pain Management Compound In Pre-Clinical Study

reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.